IBRX FY 2024 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+2270.6% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$344M-2334.2% margin

Net Income

-$414M-2804.8% margin

EPS (Diluted)

$-0.62

Cash Flow

Operating Cash Flow

-$391M

Free Cash Flow

-$398M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$383M

Total Liabilities

$871M

Stockholders' Equity

-$489M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$622,000	+2270.6%
Gross Profit	$15M	$622,000	+2270.6%
Operating Income	-$344M	-$362M	+5.0%
Net Income	-$414M	-$583M	+29.1%